Aicardi-goutières Syndrome
📧 Sign up to get email alerts when something new happens for Aicardi-goutières Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: TPN-101 in Aicardi-Goutières Syndrome (AGS) [Phase 2]
Phase 2 trial of TPN-101 for Aicardi-Goutières syndrome has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: Reverse Transcriptase Inhibitors in AGS [Phase 2]
A Phase 2 clinical trial evaluating reverse transcriptase inhibitors in Aicardi-Goutières syndrome has completed.
-
CLINICAL_TRIALS withdrawal · 2025-05-01Clinical Trial Update: Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial of reverse transcriptase inhibitors for Aicardi Goutières Syndrome was withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome
A clinical trial evaluating anti-JAK1 inhibitors in patients with Aicardi-Goutières Syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: JAK Inhibitor Treatment in AGS [Phase 2]
Phase 2 trial of a JAK inhibitor in Aicardi-Goutières syndrome has completed, with results posted on 2025-02-12.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS approval · 2025-01-17Clinical Trial Update: Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
The update notes that Eli Lilly's baricitinib has been approved for marketing for autoinflammatory syndromes including CANDLE, Juvenile Derm…
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome [Phase 2]
A Phase 2 clinical trial evaluating inhibition of reverse transcription in Aicardi-Goutières Syndrome has completed.